このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Vita Life Sciences バランスシートの健全性

財務の健全性基準チェック /66

Vita Life Sciencesの総株主資本はA$43.3M 、総負債はA$0.0で、負債比率は0%となります。総資産と総負債はそれぞれA$59.8MとA$16.5Mです。 Vita Life Sciencesの EBIT はA$11.9Mで、利息カバレッジ比率-23.8です。現金および短期投資はA$24.6Mです。

主要情報

負債資本比率

AU$0

負債

インタレスト・カバレッジ・レシオ	-23.8x
現金	AU$24.63m
エクイティ	AU$43.33m
負債合計	AU$16.48m
総資産	AU$59.81m

財務の健全性に関する最新情報

更新なし

Recent updates

財務状況分析

短期負債: VLSの短期資産 ( A$48.3M ) が短期負債 ( A$16.2M ) を超えています。

長期負債: VLSの短期資産 ( A$48.3M ) が長期負債 ( A$260.0K ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: VLSは負債がありません。

負債の削減: VLS負債比率が9.3%であった 5 年前と比べて負債がありません。

債務返済能力: VLSには負債がないため、営業キャッシュフローでカバーする必要はありません。

インタレストカバレッジ: VLSには負債がないため、利息支払いの負担は問題になりません。

Vita Life Sciences バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Recent updates

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Upcoming dividend of AU$0.06 per share

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share at 3.7% yield

Less than half of directors are independent

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

No independent directors

No independent directors

No independent directors

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

Upcoming dividend of AU$0.033 per share at 3.9% yield

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

No independent directors

No independent directors

No independent directors

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Less than half of directors are independent

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Less than half of directors are independent

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.028 per share

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

Upcoming Dividend of AU$0.015 Per Share

Earnings released

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

健全な企業の発掘

財務の健全性基準チェック /66